Evaluation of the use of Ranitidine in diabetic patients with severe infection (sepsis)

Phase 2

Recruiting

• Conditions: Diabetes Mellitus; sepsis; septicaemia; septic shock.; A41.9; C01.539.757; C01.539.757.800

• Registration Number: RBR-7m4v7b
• Lead Sponsor: Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-07-30
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patient with age greater than 18 years; Admitted to the Emergency Unit of Clinical Hospital of Ribeirão Preto medical school of University of São Paulo (UE-HCFMRP/USP); diagnosis of diabetes mellitus or serum glucose > 200 mg / dL at the admission; diagnosis of severe sepsis or septic shock; ability of the patient or his or her legal representative to decide whether or not to participate in the survey before completing 48 hours of admission.

Exclusion Criteria

Septic Patients who do not have the criteria for severe sepsis or septic shock; continuous use of ranitidine or other H2 antagonist; hypersensitivity to ranitidine or other H2 blockers; pregnant women; participation in another study; diagnosis of HIV; realization of chemotherapy in the last 30 days; palliative care; lymphoproliferative disease; refusal to signing the consent form (CF) or not to participate in the study; need of procedure or examination with contrast which requires the use of ranitidine as premedication.

Study & Design

• Study Type: Intervention
• Study Design: Not specified